Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials

Lancet

Volumn 358, Issue 9294, 2001, Pages 1668-1675

  Ferrari, Michel D ^a   Roon, Krista I ^a   Lipton, Richard B ^b,c   Goadsby, Peter J ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Innovative Medical Research Inc   (United States)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MIGRAINE; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT;

EID: 0035904760     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06711-3     Document Type: Article

References (35)

1. Migraine
2. Quality standards subcommittee of the American Academy of Neurology: Practice parameter - Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus
3. Ergotamine in the acute treatment of migraine - A review and European consensus
4. Serotonin and migraine
5. The pharmacology of headache
6. Controversies in headache. The mode of action of sumatriptan is vascular? A debate
7. 1B/1D agonists in migraine: Comparative pharmacology and its therapeutic implications
8. Tolerability of sumatriptan: Clinical trials and post-marketing experience
9. 1B/1D agonists) in migraine: Methods and detailed results of a meta-analysis of 53 trials
10. Methodology of clinical trials of sumatriptan in migraine and cluster headache
11. Guidelines for controlled trials of drugs in migraine: 2nd edn
12. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat
13. A comparative review of pharmacology, pharmacokinetics and efficacy of triptans in migraine
14. Absorption of effervescent aspirin during migraine
15. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?
16. Determinants of patient satisfaction with migraine therapy
17. Risk factors for headache recurrence after sumatriptan: A study in 366 migraine patients
18. Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrence
19. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: A placebo-controlled, outpatient study
20. Sumatriptan misuse in daily chronic headache
21. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan
22. How to assess and compare drugs in the management of migraine: Success rates in terms of response and recurrence
23. Headache classification committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
24. Meta-analysis in clinical trials
25. Random effect models
26. General parametric approach to the meta-analysis of randomized clinical trials
27. Using numerical results from systematic reviews in clinical practice
28. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine; defining the optimum doses of oral sumatriptan
29. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
30. Within-patient consistency of response of rizatriptan for treating migraine
31. Effects of encapsulation on absorption of sumatriptan tablets: Data from healthy volunteers and patients during a migraine
32. Coronary side-effect potential of current and prospective antimigraine drugs
33. Characteristics and determinants of sumatriptan-associated chest pain
34. The subcutaneous sumatriptan international study group: Treatment of migraine attacks with sumatriptan